Intermittent MEK inhibition for the treatment of metastatic uveal melanoma

INTRODUCTION: Uveal melanoma (UM) is associated with poor outcomes in the metastatic setting and harbors activating mutations resulting in upregulation of MAPK signaling in almost all cases. The efficacy of selumetinib, an oral allosteric inhibitor of MEK1/2, was limited when administered at a conti...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Shaheer, Patel, Sapna P., Shoushtari, Alexander N., Ambrosini, Grazia, Cremers, Serge, Lee, Shing, Franks, Lauren, Singh-Kandah, Shahnaz, Hernandez, Susana, Sender, Naomi, Vuolo, Kristina, Nesson, Alexandra, Mundi, Prabhjot, Izar, Benjamin, Schwartz, Gary K., Carvajal, Richard D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557946/
https://www.ncbi.nlm.nih.gov/pubmed/36249046
http://dx.doi.org/10.3389/fonc.2022.975643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557946/
https://www.ncbi.nlm.nih.gov/pubmed/36249046
http://dx.doi.org/10.3389/fonc.2022.975643

Ejemplares similares